By Fineline Cube 
US-based medical device giant Boston Scientific Corporation (NYSE: BSX) has announced a definitive acquisition agreement with fellow US firm Intera Oncology Inc., a company specializing in devices for the treatment of colorectal cancer and cholangiocarcinoma. The transaction is anticipated to be completed in the first half of 2025, marking a significant expansion for Boston Scientific into the field of oncology.
Expanding Boston Scientific’s Oncology Portfolio with Intera’s Technology
The acquisition will provide Boston Scientific with access to Intera’s Intera 3000 Hepatic Artery Infusion Pump and floxuridine, a chemotherapy agent, both of which have received marketing approval in the US. This strategic move will bolster Boston Scientific’s offerings in the treatment of liver tumors, particularly those resulting from metastatic colorectal cancer.
Intera 3000 Pump and Its Role in Liver Cancer Treatment
The Intera 3000 pump is a critical tool in the administration of hepatic artery infusion (HAI) therapy, designed to treat liver tumors primarily caused by metastatic colorectal cancer. The pump’s acquisition by Boston Scientific will enhance the company’s ability to provide targeted, localized treatment options for patients with liver cancer, improving outcomes and quality of life.-Fineline Info & Tech